Tissue Reagents PD-L1

 

Contact a Rep HTML

Request more information about PD-L1.

Please complete the form below to speak with a Roche representative.

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overview

VENTANA PD-L1 assays generate results you can trust, so that you can make timely diagnostic decisions and therapeutic choices. We support your expertise by providing you with the tools that you need to successfully implement these assays into your laboratory and interpret them proficiently.

VENTANA predictive assays identify patients who are most likely to respond to specific therapies.

VENTANA PD-L1 (SP142) Assay

VENTANA PD-L1 (SP142) Assay gives you the confidence to appropriately identify urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) patients most likely to benefit from TECENTRIQ® (atezolizumab). FDA approved.

Learn more

VENTANA PD-L1 (SP263) Assay

VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying urothelial carcinoma (UC) patients most likely to benefit from IMFINZI (durvalumab) FDA approved.

Learn more

Explore
 

VENTANA PD-L1 (SP142) Assay

PD-L1 assay | Guiding immunotherapy

The VENTANA PD-L1 (SP142) Assay identifies patients most likely to benefit from TECENTRIQ® (atezolizumab). FDA approved.

> Click here for the US testing information

The PD-L1 immunologic checkpoint

Learn more


The tumor microenvironment

Learn more


Non-small cell lung cancer

Using the right test to determine PD-L1 status for immunotherapy options is important, and the VENTANA PD-L1 (SP142) Assay is the only FDA approved test for TECENTRIQ. This innovative assay is the first to evaluate patient PD-L1 expression using both tumor cell (TC) and tumor-infiltrating immune cell (IC) staining. Determining a patient’s PD-L1 expression level can give insight to the overall survival that may be achieved from TECENTRIQ.*

The VENTANA PD-L1 (SP142) Assay:

  • FDA approved to assess NSCLC patient treatment benefit from TECENTRIQ
  • Informative for the clinician of a patient’s potential overall survival
  • Novel scoring algorithm using PD-L1 staining in both TC and IC
  • Designed to enhance visual contrast of immune cell staining within the tumor microenvironment

The PD-L1 (SP142) Assay gives you the confidence to guide immunotherapy decisions in NSCLC.

*All randomized patients in a NSCLC phase III study observed benefit from TECENTRIQ regardless of PD-L1 status.


Urothelial carcinoma

Using the right test to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP142) Assay* is the first and only FDA approved test predictive for TECENTRIQ in urothelial carcinoma (UC) patients. This novel assay is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.

The VENTANA PD-L1 (SP142) Assay:

  • FDA approved to predict UC patient response to TECENTRIQ
  • Designed to enhance visual contrast of immune cell staining within the tumor microenvironment
  • Stains PD-L1 in both tumor cells (TC) and tumor-infiltrating immune cells (IC)

*In the US only available on the VENTANA BenchMark ULTRA Instrument.

 

VENTANA PD-L1 (SP263) Assay

PD-L1 predictive assays | Guiding immunotherapy

VENTANA PD-L1 (SP263) Assay guides immunotherapy decisions by identifying Urothelial carcinoma (UC) patients most likely to benefit from IMFINZI (durvalumab) FDA approved.

> Click here for the US testing information

The PD-L1 immunologic checkpoint

Learn more


The tumor microenvironment

Learn more


Urothelial carcinoma (FDA approved)

Empowering pathologist to answer PD-L1 questions

The VENTANA PD-L1 (SP263) Assay* is the clinical trial enrollment assay for IMFINZI (durvalumab) and the only PD-L1 assay validated to assess UC patient treatment benefit from this PD-L1 inhibitor. Using a validated assay to determine PD-L1 status for immunotherapies is important. VENTANA PD-L1 (SP263) Assay equips pathologists by:

  • Identifying urothelial carcinoma patients most likely to benefit from IMFINZI (durvalumab)
  • Producing robust PD-L1 staining in both tumor cells (TC) and tumor-infiltrating immune cells (IC)
  • Providing access to multiple immunotherapy options for different cancer types

*In the US only available on the BenchMark ULTRA Instrument

Resources

Outside of Pepper mode, this text will be replaced by the resource cards.

Contact Us

Outside of Pepper mode, this text will be replaced by the content added in the above "Contact a Rep HTML" code editor.

 

 
Virtual Slide Box Strategic Resource Center